No pharmaceutical opinion available for this interaction.
Lopinavir / ritonavir can inhibit the metabolism (CYP 3A4) and increase the plasma concentration of Glyburide.
Lopinavir / ritonavir can induce the metabolism (CYP 2C9) and decrease the plasma concentration of Glyburide.
3A4 (major), 13 identified metabolites, 5 of these metabolites are linked to the metabolism of ritonavir, transporters: MRP1, MRP2, OATP1A2, OATP1B1, P-gp
2C19 (strong), 1A2, 2C9 (moderate) UGT (moderate)
3A4 and 2D6 (strong), transporters: BCRP, MRP2, OATP1A2, OATP1B1, OATP1B3, OATP2B1, P-gp
2C9 and 3A4
Possible increase of the hypoglycemic effect.
Possible decrease of clinical efficacy.
Pharmacodynamic effects difficult to predict.
Monitor the clinical efficacy and appearance of adverse effects.
Metformin, DPP-4 Inhibitors, GLP-1 Agonists
Signs and symptoms of hypoglycemia : headache, dizziness, tiredness, rapid heartbeat, nervousness, shakiness, nausea and sweating.